Creative Biomart Blog

Tue, 2024/06/11

Targeting SOX13 to Overcome Iron Death Resistance in Gastric Cancer

Gastric cancer (GC) is the fifth most common cancer and the fourth leading cause of cancer-related deaths in the world. Despite significant progress in gastric cancer management, the prognosis of patients with advanced gastric cancer remains poor. Cisplatin-based chemotherapy is still the first-line adjuvant or neoadjuvant treatment for advanced gastric cancer, but understanding chemotherapy resistance remains a barrier to clinical efficacy. Cancer immunotherapy, including immune checkpoint inhibitors, has become an effective treatment for various types of cancer. However, due to drug resistan

Tue, 2024/06/11

A New Strategy For Tumor Growth Inhibition: BCL9/BCL9L Targeted Therapy And cDC1 Activation

Zhu Di and Wang Mingwei from Fudan University jointly published a research paper titled "Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration" in Signal Transmission and Targeted Therapy. This study indicates that targeting BCL9/BCL9L enhances antigen presentation by stimulating cDC1 activation and infiltration into tumors. Knockout mice with novel inhibitors hsBCL9z96 or BCL9/BCL9L can significantly delay tumor growth and promote anti-tumor CD8+T cell response by inhibiting BCL9/BCL9L. Mechanistically, t

Tue, 2024/06/11

Topological Generation Pathways of Multiple Transmembrane Proteins

More than half of the approximately 5000 membrane proteins synthesized on the endoplasmic reticulum membrane of human cells are multi-transmembrane proteins. Multiple transmembrane proteins play important roles in cells as ion channels, transporters, receptor proteins, transmembrane enzymes, and more. These functions rely heavily on the polarity and charged amino acids of the transmembrane domain, and the polar and charged amino acid side chains typically exhibit lipid-repellent properties, resulting in lower hydrophobicity of the transmembrane helix (TMH) they are located in. Statistics show

Mon, 2024/06/03

Phase I Research Data on Bispecific IgG Degradation Agents Released

Biohaven has released Phase I data for its IgG degrading agent BHV-1300 and stated that BHV-1300 rapidly and selectively reduces IgG in a dose-dependent manner. BHV-1300 is a bispecific protein degrading agent under research, and its mechanism of action is to search for and bind with pathogenic IgG, bringing it to the liver for degradation. This gives BHV-1300 the potential to treat antibody-driven diseases such as rheumatoid arthritis, myasthenia gravis, and systemic lupus erythematosus. Preliminary Phase I data shows that some patients have IgG concentrations as low as 50% to 70% o

Sat, 2024/04/27

The Key Role of HIF-1Α in Promoting the Activation of Embryonic Zygotic Genome

The development of normal mammals occurs in a hydrogen-peroxide environment, and the adaptive response to hydrogen peroxide is considered a landmark event for embryo survival in hypoxic fallopian tubes and intrauterine environments, thus playing a crucial role in mammalian evolution. Due to the gene deletion of hypoxia-inducible factor (HIF) (oxygen-sensitive transcription factor), the response to physO2 is insufficient, resulting in embryo loss during implantation or severe developmental defects shortly after implantation. However, due to significant morphological defects occurring mainly dur

Sat, 2024/04/27

The Gasdermin Family: Emerging Therapeutic Targets for Diseases

The recently discovered Gasdermin (GSDM) protein family plays a crucial role in regulating pyroptosis, a special form of programmed cell death (PCD). In humans, six homologous genes have been identified: GSDMA-E and DFNB59. The role of GSDMs in pyroptosis has been confirmed, and GSDMA-E has been shown to undergo protein hydrolysis processing, leading to the release of n-terminal (NT) fragments that assemble into pores on the plasma membrane (PM). These GSDM pores can penetrate PM and mitochondrial membranes, leading to inflammatory cell death. In addition, they promote the extracellular sec

Fri, 2024/04/26

QDPR Deficiency Leads to Immunosuppression of Pancreatic Cancer

The research team led by Lin Dongxin, Zheng Jian, and Wang Liqin from the Cancer Prevention and Treatment Center of Sun Yat-sen University and the National Key Laboratory of Malignant Tumor Prevention and Treatment in South China published a research paper titled "QDPR deficiency drives immune suppression in pancreatic cancer" in the Cell Metabolism journal. This study found that in pancreatic ductal adenocarcinoma (PDAC), quinone dihydropterin reductase (QDPR) deficiency leads to immunosuppression of pancreatic cancer. QDPR deficiency leads to resistance to immune checkpoint blockade (ICB)

Fri, 2024/04/26

Key Targets in Molecular Characteristics of Parkinson's disease at Different Stages of Progression

The neuroinflammation associated with Parkinson's disease (PD) has attracted widespread attention due to abnormal protein aggregation, among which glycosylation, as a post-translational modification process that maintains protein stability, plays an important role in this process. Recently, in a research report published in the international journal PNAS Nexus titled " Changes in tissue protein N-glycosylation and associated molecular signature occur in the human Parkinsonian brain in a region-specific manner", scientists from institutions such as the University of Galway identified for the